CSIMarket
 


Enveric Biosciences Inc   (ENVB)
Other Ticker:  
 
 

ENVB's Net Income Growth by Quarter and Year

Enveric Biosciences Inc 's Net Income results by quarter and year




ENVB Net Income (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - -8.69 -42.11 -2.55
III Quarter September -2.82 -2.49 -2.71 -0.96
II Quarter June -6.36 -2.80 -0.91 -1.57
I Quarter March -4.69 -4.52 -3.25 -1.78
FY   -13.87 -18.50 -48.98 -6.86



ENVB Net Income third quarter 2023 Y/Y Growth Comment
Enveric Biosciences Inc in the third quarter 2023 recorded net loss of $ -2.82 millions.

According to the results reported in the third quarter 2023, Enveric Biosciences Inc achieved the best Net Income growth in Major Pharmaceutical Preparations industry. While Enveric Biosciences Inc ' s Net Income no change of % ranks overall at the positon no. in the third quarter 2023.




ENVB Net Income ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Enveric Biosciences Inc 's third quarter 2023 Net Income $ -2.82 millions ENVB's Income Statement
Enveric Biosciences Inc 's third quarter 2022 Net Income $ -2.49 millions Quarterly ENVB's Income Statement
New: More ENVB's historic Net Income Growth >>


ENVB Net Income (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Net Income third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Net Income third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Net Income by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Enveric Biosciences Inc 's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ENVB's III. Quarter Q/Q Net Income Comment
Despite the fact, that Enveric Biosciences Inc in the III. Quarter 2023 admitted net loss of $ -2.82 millions, it should be point out, that this are slight up side relative to the -6.36 millions in the second quarter.

Within Major Pharmaceutical Preparations industry Enveric Biosciences Inc achieved highest sequential Net Income growth. While Enveric Biosciences Inc 's Net Income growth quarter on quarter, overall rank is .


Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ENVB's III. Quarter Q/Q Net Income Comment
Although Enveric Biosciences Inc in the III. Quarter 2023 admitted net loss of $ -2.82 millions, management mentioned, that this point to slight up side relative to the -6.36 millions in the second quarter.

Within Major Pharmaceutical Preparations industry Enveric Biosciences Inc achieved highest sequential Net Income growth. While Enveric Biosciences Inc 's Net Income growth quarter on quarter, overall rank is .


Enveric Biosciences Inc 's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Net Income 12 Months Ending $ -22.57 $ -22.23 $ -18.67 $ -18.50 $ -51.92
Y / Y Net Income Growth (TTM) - - - - -
Year on Year Net Income Growth Overall Ranking # # # # #
Seqeuential Net Income Change (TTM) - - - - -
Seq. Net Income Growth (TTM) Overall Ranking # # # # #




Cumulative Net Income growth Comment


Enveric Biosciences Inc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Net Income growth Comment


Enveric Biosciences Inc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Net Income Growth
Major Pharmaceutical Preparations Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
ENVB's Net Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for ENVB's Competitors
Net Income Growth for Enveric Biosciences Inc 's Suppliers
Net Income Growth for ENVB's Customers

You may also want to know
ENVB's Annual Growth Rates ENVB's Profitability Ratios ENVB's Asset Turnover Ratio ENVB's Dividend Growth
ENVB's Roe ENVB's Valuation Ratios ENVB's Financial Strength Ratios ENVB's Dividend Payout Ratio
ENVB's Roa ENVB's Inventory Turnover Ratio ENVB's Growth Rates ENVB's Dividend Comparisons



Companies with similar Net Income no change for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Net Income for the quarter ending Sep 30 2023
Gilead Sciences Inc 21.61%$ 21.613 millions
Neurocrine Biosciences Inc 21.31%$ 21.314 millions
Docgo Inc 20.50%$ 20.505 millions
Progyny Inc 20.34%$ 20.339 millions
Bristol myers Squibb Company20.27%$ 20.274 millions
Dexcom Inc 19.27%$ 19.269 millions
Idexx Laboratories Inc17.29%$ 17.295 millions
Biomx Inc 16.61%$ 16.608 millions
Ensign Group Inc13.74%$ 13.737 millions
Zoetis Inc 12.88%$ 12.879 millions
United Therapeutics Corporation11.83%$ 11.826 millions
Edwards Lifesciences Corporation11.70%$ 11.703 millions
Vertex Pharmaceuticals Inc11.26%$ 11.263 millions
Iqvia Holdings Inc 7.07%$ 7.067 millions
Medpace Holdings Inc 6.85%$ 6.850 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com